RBCC Enters New World of Opportunity

Emirates PharmaAdvertisement

Rainbow Coral Corp. positioned itself at the cutting edge of biotechnology innovation today by joining forces with BioHouston, Inc., one of the nation’s preeminent drivers of life sciences research and commercialization.

Home to the world’s largest medical complex, Houston, Texas, is the fastest-growing biotechnology hotspot in the U.S. BioHouston is an academic and business collaborative that brings together innovation heavyweights like Baylor College of Medicine and M.D. Anderson Cancer Center with powerful investors such as Baker Botts and JP Morgan Chase to develop and commercialize the very latest biotech products and ideas.

Membership in BioHouston opens new doors for RBCC to become major players in the global biotechnology industry. Rainbow Coral gains access to some of the brightest minds and deepest pockets involved in the research, development and marketing of new life sciences breakthroughs.

By joining BioHouston, RBCC solidifies its position as a rising star in biotech commercialization. It’s a major step in the company’s aggressive global growth strategy. RBCC anticipates a new level of participation in shaping the future of healthcare around the world.

Through its biotech division, Rainbow BioSciences, RBCC is working to develop new medical and research technology innovations to compete alongside companies such as Cell Therapeutics, Inc. Biogen Idec Inc. , Abbott Laboratories and Elan Corp. (NYSE: ELN).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. 

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

 

 

 

Emirates PharmaAdvertisement